世界の去勢抵抗性前立腺がん治療市場インサイト:2028年までの予測

出版:QYResearch(QYリサーチ) 出版年月:2022年12月

Global Castrate Resistant Prostate Cancer Therapeutics Market Insights, Forecast to 2028
世界の去勢抵抗性前立腺がん治療市場インサイト:2028年までの予測

ページ数126
図表数 183
価格
シングルユーザライセンスUSD 4,900
マルチユーザライセンスUSD 7,350
エンタープライズライセンスUSD 9,800
種別英文調査報告書

レポート目次  お問合せ・ご注文  価格・納期について

無料サンプル

Market Analysis and Insights: Global Castrate Resistant Prostate Cancer Therapeutics Market
Due to the COVID-19 pandemic, the global market for Castrate Resistant Prostate Cancer Therapeutics estimated at US$ 15,175.51 million in the year 2022, is projected to reach a revised size of US$ 28,717.44 million by 2028, growing at a CAGR of 11.22% during the forecast period 2022-2028.
The USA market for Castrate Resistant Prostate Cancer Therapeutics is estimated to increase from $ 6,215.82 million in 2022 to reach $ 11,706.05 million by 2028, at a CAGR of 10.89% during the forecast period of 2023 through 2028.
The China market for Castrate Resistant Prostate Cancer Therapeutics is estimated to increase from $ 1,224.11 million in 2022 to reach $ 2,596.61 million by 2028, at a CAGR of 13.25% during the forecast period of 2023 through 2028.
The Europe market for Castrate Resistant Prostate Cancer Therapeutics is estimated to increase from $ 4,273.15 million in 2022 to reach $ 8,083.69 million by 2028, at a CAGR of 10.92% during the forecast period of 2023 through 2028.
The global key companies of Castrate Resistant Prostate Cancer Therapeutics include Pfizer/Astellas(Xtandi), Johnson & Johnson, AstraZeneca/Merck (Lynparza), Bayer, Jiangsu Jiangsu Hengrui Pharmaceuticals Pharmaceuticals, CTTQ, Sanofi, Hansoh, and Clovis Oncology, etc. In 2021, the global top five players had a share approximately 78.19 % in terms of revenue.
Report Includes
This report presents an overview of global market for Castrate Resistant Prostate Cancer Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Castrate Resistant Prostate Cancer Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Castrate Resistant Prostate Cancer Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Castrate Resistant Prostate Cancer Therapeutics revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Castrate Resistant Prostate Cancer Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Castrate Resistant Prostate Cancer Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer/Astellas (Xtandi), Johnson & Johnson, AstraZeneca/Merck (Lynparza), Bayer, Jiangsu Jiangsu Hengrui Pharmaceuticals Pharmaceuticals, CTTQ, Sanofi, Hansoh, and Clovis Oncology, etc.
Segment by Type
Hormonal Therapy
Chemotherapy
Others

Segment by Application
Hospital
Specialty Clinic
Others

By Company
Pfizer/Astellas(Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Jiangsu Hengrui Pharmaceuticals Pharmaceuticals
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical

By Region
North America
United States
Canada

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia

Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe

Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
Others

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Castrate Resistant Prostate Cancer Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castrate Resistant Prostate Cancer Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 9: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Castrate Resistant Prostate Cancer Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions


目次

Tables and Figures

1 Report Overview 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1
1.2.2 Hormonal Therapy 3
1.2.3 Chemotherapy 3
1.2.4 Others 4
1.3 Market by Application 4
1.3.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Application: 2017 VS 2021 VS 2028 5
1.3.2 Hospital 6
1.3.3 Specialty Clinic 7
1.3.4 Others 7
1.4 Study Objectives 7
1.5 Years Considered 8
2 Global Growth Trends 9
2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Perspective (2017-2028) 9
2.2 Castrate Resistant Prostate Cancer Therapeutics Growth Trends by Region 10
2.2.1 Castrate Resistant Prostate Cancer Therapeutics Market Size by Region: 2017 VS 2021 VS 2028 10
2.2.2 Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Region (2017-2022) 11
2.2.3 Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Region (2023-2028) 12
2.3 Castrate Resistant Prostate Cancer Therapeutics Market Dynamics 13
2.3.1 Castrate Resistant Prostate Cancer Therapeutics Industry Trends 13
2.3.2 Castrate Resistant Prostate Cancer Therapeutics Market Drivers 14
2.3.3 Castrate Resistant Prostate Cancer Therapeutics Market Challenges 15
3 Competition Landscape by Key Players 16
3.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue 16
3.1.1 Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Revenue (2017-2022) 16
3.1.2 Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Players (2019-2022) 17
3.2 Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 18
3.3 Players Covered: Ranking by Castrate Resistant Prostate Cancer Therapeutics Revenue 19
3.4 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio 20
3.4.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Concentration Ratio (CR5) 20
3.4.2 Global Top 10 and Top 5 Companies by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2021 21
3.5 Castrate Resistant Prostate Cancer Therapeutics Key Players Head office and Area Served 22
3.6 Key Players Castrate Resistant Prostate Cancer Therapeutics Product Solution and Service 22
3.7 Date of Enter into Castrate Resistant Prostate Cancer Therapeutics Market 23
3.8 Mergers & Acquisitions, Expansion Plans 23
4 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Type 26
4.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Type (2017-2022) 26
4.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (2023-2028) 27
5 Castrate Resistant Prostate Cancer Therapeutics Breakdown Data by Application 28
5.1 Global Castrate Resistant Prostate Cancer Therapeutics Historic Market Size by Application (2017-2022) 28
5.2 Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (2023-2028) 29
6 North America 30
6.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size (2017-2028) 30
6.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type 30
6.2.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) 30
6.2.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) 31
6.2.3 North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028) 31
6.3 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application 32
6.3.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) 32
6.3.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) 32
6.3.3 North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028) 33
6.4 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country 33
6.4.1 North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022) 33
6.4.2 North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2023-2028) 34
6.4.3 United States 35
6.4.4 Canada 35
7 Europe 36
7.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size (2017-2028) 36
7.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Type 36
7.2.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) 36
7.2.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) 37
7.2.3 Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028) 37
7.3 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Application 38
7.3.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) 38
7.3.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) 38
7.3.3 Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028) 39
7.4 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country 39
7.4.1 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022) 39
7.4.2 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028) 40
7.4.3 Germany 41
7.4.4 France 41
7.4.5 U.K. 42
7.4.6 Italy 42
7.4.7 Russia 43
8 Asia-Pacific 44
8.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size (2017-2028) 44
8.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Type 44
8.2.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) 44
8.2.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) 45
8.2.3 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028) 45
8.3 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Application 46
8.3.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) 46
8.3.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) 46
8.3.3 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028) 47
8.4 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region 47
8.4.1 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2017-2022) 47
8.4.2 Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2023-2028) 48
8.4.3 China 49
8.4.4 Japan 49
8.4.5 South Korea 50
8.4.6 Southeast Asia 50
8.4.7 India 51
8.4.8 Australia 51
9 Latin America 52
9.1 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size (2017-2028) 52
9.2 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type 52
9.2.1 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) 52
9.2.2 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) 53
9.2.3 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028) 53
9.3 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application 54
9.3.1 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) 54
9.3.2 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) 54
9.3.3 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028) 55
9.4 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country 55
9.4.1 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022) 55
9.4.2 Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028) 56
9.4.3 Brazil 57
9.4.4 Mexico 57
9.4.5 Argentina 58
10 Middle East & Africa 59
10.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size (2017-2028) 59
10.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Type 59
10.2.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) 59
10.2.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) 60
10.2.3 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028) 60
10.3 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Application 61
10.3.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) 61
10.3.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) 61
10.3.3 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028) 62
10.4 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country 62
10.4.1 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022) 62
10.4.2 Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028) 63
10.4.3 GCC Countries 64
10.4.4 Turkey 64
10.4.5 Egypt 65
10.4.6 South Africa 65
11 Key Players Profiles 66
11.1 Pfizer/Astellas(Xtandi) 66
11.1.1 Pfizer/Astellas (Xtandi) Company Details 66
11.1.2 Pfizer/Astellas(Xtandi) Business Overview 67
11.1.3 Pfizer/Astellas(Xtandi) Castrate Resistant Prostate Cancer Therapeutics Introduction 68
11.1.4 Pfizer/Astellas(Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 68
11.1.5 Pfizer/Astellas(Xtandi) Recent Development 69
11.2 Johnson & Johnson 69
11.2.1 Johnson & Johnson Company Details 69
11.2.2 Johnson & Johnson Business Overview 70
11.2.3 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Introduction 70
11.2.4 Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 71
11.3 AstraZeneca/Merck (Lynparza) 72
11.3.1 AstraZeneca/Merck (Lynparza) Company Details 72
11.3.2 AstraZeneca/Merck (Lynparza) Business Overview 73
11.3.3 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Introduction 74
11.3.4 AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 74
11.3.5 AstraZeneca/Merck (Lynparza) Recent Development 75
11.4 Bayer 75
11.4.1 Bayer Company Details 76
11.4.2 Bayer Business Overview 76
11.4.3 Bayer Castrate Resistant Prostate Cancer Therapeutics Introduction 77
11.4.4 Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 78
11.5 Jiangsu Hengrui Pharmaceuticals 78
11.5.1 Jiangsu Hengrui Pharmaceuticals Company Details 79
11.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview 79
11.5.3 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Introduction 79
11.5.4 Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 80
11.5.5 Jiangsu Hengrui Pharmaceuticals Recent Development 81
11.6 CTTQ 81
11.6.1 CTTQ Company Details 81
11.6.2 CTTQ Business Overview 81
11.6.3 CTTQ Castrate Resistant Prostate Cancer Therapeutics Introduction 82
11.6.4 CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 83
11.6.5 CTTQ Recent Development 84
11.7 Sanofi 85
11.7.1 Sanofi Company Details 85
11.7.2 Sanofi Business Overview 85
11.7.3 Sanofi Castrate Resistant Prostate Cancer Therapeutics Introduction 86
11.7.4 Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 87
11.7.5 Sanofi Recent Development 87
11.8 Hansoh 88
11.8.1 Hansoh Company Details 88
11.8.2 Hansoh Business Overview 88
11.8.3 Hansoh Castrate Resistant Prostate Cancer Therapeutics Introduction 89
11.8.4 Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 90
11.8.5 Hansoh Recent Development 91
11.9 Clovis Oncology 92
11.9.1 Clovis Oncology Company Details 92
11.9.2 Clovis Oncology Business Overview 92
11.9.3 Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Introduction 93
11.9.4 Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 93
11.9.5 Clovis Oncology Recent Development 94
11.10 Zhendong Pharmaceutical 95
11.10.1 Zhendong Pharmaceutical Company Details 95
11.10.2 Zhendong Pharmaceutical Business Overview 95
11.10.3 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Introduction 96
11.10.4 Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 97
12 Analyst’s Viewpoints/Conclusions 98
13 Appendix 99
13.1 Research Methodology 99
13.1.1 Methodology/Research Approach 99
13.1.2 Data Source 102
13.2 Disclaimer 105
13.3 Author Details 106

Table 1. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 1
Table 2. Key Players of Hormonal Therapy 3
Table 3. Key Players of Chemotherapy 4
Table 4. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 5
Table 5. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 10
Table 6. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2017-2022) & (US$ Million) 11
Table 7. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2017-2022) 11
Table 8. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million) 12
Table 9. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2023-2028) 12
Table 10. Castrate Resistant Prostate Cancer Therapeutics Market Trends 13
Table 11. Castrate Resistant Prostate Cancer Therapeutics Market Drivers 14
Table 12. Castrate Resistant Prostate Cancer Therapeutics Market Challenges 15
Table 13. Global Castrate Resistant Prostate Cancer Therapeutics Revenue by Players (2019-2022) & (US$ Million) 16
Table 14. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Players (2019-2022) 17
Table 15. Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castrate Resistant Prostate Cancer Therapeutics as of 2021) 18
Table 16. Ranking of Global Top Castrate Resistant Prostate Cancer Therapeutics Companies by Revenue (US$ Million) in 2021 19
Table 17. Global 5 Largest Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue (CR5) & (2019-2022) 20
Table 18. Key Players Headquarters and Area Served 22
Table 19. Key Players Castrate Resistant Prostate Cancer Therapeutics Product Solution and Service 22
Table 20. Date of Enter into Castrate Resistant Prostate Cancer Therapeutics Market 23
Table 21. Mergers & Acquisitions, Expansion Plans 23
Table 22. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million) 26
Table 23. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Type (2017-2022) 26
Table 24. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million) 27
Table 25. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Type (2023-2028) 27
Table 26. Global Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million) 28
Table 27. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Application (2017-2022) 28
Table 28. Global Castrate Resistant Prostate Cancer Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million) 29
Table 29. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Application (2023-2028) 29
Table 30. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million) 30
Table 31. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) & (US$ Million) 31
Table 32. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million) 32
Table 33. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) & (US$ Million) 32
Table 34. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022) & (US$ Million) 33
Table 35. North America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028) & (US$ Million) 34
Table 36. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million) 36
Table 37. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) & (US$ Million) 37
Table 38. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million) 38
Table 39. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) & (US$ Million) 38
Table 40. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022) & (US$ Million) 39
Table 41. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028) & (US$ Million) 40
Table 42. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million) 44
Table 43. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) & (US$ Million) 45
Table 44. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million) 46
Table 45. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) & (US$ Million) 46
Table 46. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2017-2022) & (US$ Million) 47
Table 47. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2023-2028) & (US$ Million) 48
Table 48. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million) 52
Table 49. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) & (US$ Million) 53
Table 50. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million) 54
Table 51. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) & (US$ Million) 54
Table 52. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022) & (US$ Million) 55
Table 53. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028) & (US$ Million) 56
Table 54. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2017-2022) & (US$ Million) 59
Table 55. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2023-2028) & (US$ Million) 60
Table 56. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2017-2022) & (US$ Million) 61
Table 57. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2023-2028) & (US$ Million) 61
Table 58. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2017-2022) & (US$ Million) 62
Table 59. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size by Country (2023-2028) & (US$ Million) 63
Table 60. Pfizer (Xtandi) Company Details 66
Table 61. Astellas (Xtandi) Company Details 66
Table 62. Pfizer (Xtandi) Business Overview 67
Table 63. Astellas(Xtandi) Business Overview 67
Table 64. Pfizer/Astellas(Xtandi) Castrate Resistant Prostate Cancer Therapeutics Product 68
Table 65. Pfizer/Astellas(Xtandi) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million) 68
Table 66. Pfizer/Astellas(Xtandi) Recent Development 69
Table 67. Johnson & Johnson Company Details 69
Table 68. Johnson & Johnson Business Overview 70
Table 69. Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Product 70
Table 70. Johnson & Johnson Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million) 71
Table 71. AstraZeneca (Lynparza) Company Details 72
Table 72. Merck (Lynparza) Company Details 73
Table 73. AstraZeneca (Lynparza) Business Overview 73
Table 74. Merck (Lynparza) Business Overview 73
Table 75. AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Product 74
Table 76. AstraZeneca/Merck (Lynparza) Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million) 74
Table 77. AstraZeneca/Merck (Lynparza) Recent Development 75
Table 78. Bayer Company Details 76
Table 79. Bayer Business Overview 76
Table 80. Bayer Castrate Resistant Prostate Cancer Therapeutics Product 77
Table 81. Bayer Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million) 78
Table 82. Jiangsu Hengrui Pharmaceuticals Company Details 79
Table 83. Jiangsu Hengrui Pharmaceuticals Business Overview 79
Table 84. Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Product 79
Table 85. Jiangsu Hengrui Pharmaceuticals Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million) 80
Table 86. Jiangsu Hengrui Pharmaceuticals Recent Development 81
Table 87. CTTQ Company Details 81
Table 88. CTTQ Business Overview 81
Table 89. CTTQ Castrate Resistant Prostate Cancer Therapeutics Product 82
Table 90. CTTQ Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million) 83
Table 91. CTTQ Recent Development 84
Table 92. Sanofi Company Details 85
Table 93. Sanofi Business Overview 85
Table 94. Sanofi Castrate Resistant Prostate Cancer Therapeutics Product 86
Table 95. Sanofi Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million) 87
Table 96. Sanofi Recent Development 87
Table 97. Hansoh Company Details 88
Table 98. Hansoh Business Overview 88
Table 99. Hansoh Castrate Resistant Prostate Cancer Therapeutics Product 89
Table 100. Hansoh Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million) 90
Table 101. Hansoh Recent Development 91
Table 102. Clovis Oncology Company Details 92
Table 103. Clovis Oncology Business Overview 92
Table 104. Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Product 93
Table 105. Clovis Oncology Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million) 93
Table 106. Clovis Oncology Recent Development 94
Table 107. Zhendong Pharmaceutical Company Details 95
Table 108. Zhendong Pharmaceutical Business Overview 95
Table 109. Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Product 96
Table 110. Zhendong Pharmaceutical Revenue in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) & (US$ Million) 97
Table 111. Research Programs/Design for This Report 99
Table 112. Key Data Information from Secondary Sources 103
Table 113. Key Data Information from Primary Sources 104

List of Figures

Figure 1. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Type, 2017-2028 (US$ Million) 2
Figure 2. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Type: 2021 VS 2028 2
Figure 3. Hormonal Therapy Features 3
Figure 4. Chemotherapy Features 4
Figure 5. Others Features 4
Figure 6. Global Castrate Resistant Prostate Cancer Therapeutics Market Size Growth Rate by Application, 2017-2028 (US$ Million) 5
Figure 7. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Application: 2021 VS 2028 6
Figure 8. Hospital Case Studies 6
Figure 9. Specialty Clinic Case Studies 7
Figure 10. Others Case Studies 7
Figure 11. Castrate Resistant Prostate Cancer Therapeutics Report Years Considered 8
Figure 12. Global Castrate Resistant Prostate Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028 9
Figure 13. Global Castrate Resistant Prostate Cancer Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028 10
Figure 14. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Region: 2021 VS 2028 11
Figure 15. Global Castrate Resistant Prostate Cancer Therapeutics Market Share by Players in 2021 17
Figure 16. Global Top Castrate Resistant Prostate Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castrate Resistant Prostate Cancer Therapeutics as of 2019 VS 2021) 19
Figure 17. The Top 10 and 5 Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2021 21
Figure 18. North America Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 30
Figure 19. North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028) 31
Figure 20. North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028) 33
Figure 21. North America Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2017-2028) 34
Figure 22. United States Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 35
Figure 23. Canada Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 35
Figure 24. Europe Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 36
Figure 25. Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028) 37
Figure 26. Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028) 39
Figure 27. Europe Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2017-2028) 40
Figure 28. Germany Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 41
Figure 29. France Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 41
Figure 30. U.K. Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 42
Figure 31. Italy Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 42
Figure 32. Russia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 43
Figure 33. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 44
Figure 34. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028) 45
Figure 35. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028) 47
Figure 36. Asia-Pacific Castrate Resistant Prostate Cancer Therapeutics Market Share by Region (2017-2028) 48
Figure 37. China Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 49
Figure 38. Japan Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 49
Figure 39. South Korea Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 50
Figure 40. Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 50
Figure 41. India Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 51
Figure 42. Australia Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 51
Figure 43. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 52
Figure 44. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028) 53
Figure 45. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028) 55
Figure 46. Latin America Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2017-2028) 56
Figure 47. Brazil Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 57
Figure 48. Mexico Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 57
Figure 49. Argentina Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 58
Figure 50. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 59
Figure 51. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Type (2017-2028) 60
Figure 52. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Application (2017-2028) 62
Figure 53. Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Market Share by Country (2017-2028) 63
Figure 54. GCC Countries Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 64
Figure 55. Turkey Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 64
Figure 56. Egypt Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 65
Figure 57. South Africa Castrate Resistant Prostate Cancer Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) 65
Figure 58. Pfizer/Astellas(Xtandi) Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 69
Figure 59. Johnson & Johnson Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 72
Figure 60. AstraZeneca/Merck (Lynparza) Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 75
Figure 61. Bayer Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 78
Figure 62. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 80
Figure 63. CTTQ Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 84
Figure 64. Sanofi Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 87
Figure 65. Hansoh Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 91
Figure 66. Clovis Oncology Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 94
Figure 67. Zhendong Pharmaceutical Revenue Growth Rate in Castrate Resistant Prostate Cancer Therapeutics Business (2019-2022) 97
Figure 68. Bottom-up and Top-down Approaches for This Report 101
Figure 69. Data Triangulation 102
Figure 70. Key Executives Interviewed 104


    お問合せフォーム

    • *のある項目は必須項目です。

    • レポートのタイトルは自動で入ります。

    • 無料サンプルはご購入を検討されている方向けのレポート形式等確認用資料です。
      重要記述や数値は記載されていません。予めご了承ください。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com